Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 20/20 | 0.71 |
| ▸ | RPS6KB1 | P23443 | 19/20 | 0.71 |
| ▸ | PRKCB | P05771 | 4/20 | 0.71 |
| ▸ | RPS6KA1 | Q15418 | 4/20 | 0.71 |
| ▸ | AKT2 | P31751 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9894880 | 1.00 | AKT1 (0.71) | AKT1RPS6KB1PRKCBRPS6KA1AKT2 | |
| SCHEMBL9894827 | 0.98 | AKT1 (0.69) | AKT1RPS6KB1PRKCBRPS6KA1AKT2 | |
| SCHEMBL9894826 | 0.98 | AKT1 (0.69) | AKT1RPS6KB1PRKCBRPS6KA1AKT2 | |
| SCHEMBL9895017 | 0.98 | AKT1 (0.70) | AKT1RPS6KB1PRKCBRPS6KA1AKT2 | |
| SCHEMBL9895016 | 0.98 | AKT1 (0.70) | AKT1RPS6KB1PRKCBRPS6KA1AKT2 | |
| SCHEMBL9927830 | 0.98 | AKT1 (0.70) | AKT1RPS6KB1PRKCBRPS6KA1AKT2 | |
| SCHEMBL16457510 | 0.98 | AKT1 (0.70) | AKT1RPS6KB1PRKCBRPS6KA1AKT2 | |
| SCHEMBL9927833 | 0.95 | AKT1 (0.81) | AKT1RPS6KB1PRKCBRPS6KA1AKT2 | |
| SCHEMBL16457540 | 0.95 | AKT1 (0.81) | AKT1RPS6KB1PRKCBRPS6KA1AKT2 | |
| SCHEMBL1662949 | 0.90 | AKT1 (0.84) | AKT1RPS6KB1PRKCBRPS6KA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2491032-B1 | AKT INHIBITORS | LILLY CO ELI (US) | 2014-04-16 | — | — | EP | disclosed |
| US-8436002-B2 | AKT inhibitors | ELI LILLY AND COMPANY (US) | 2013-05-07 | — | — | US | disclosed |
| US-20120149684-A1 | AKT INHIBITORS | ELI LILLY AND COMPANY (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149684-A1 | AKT INHIBITORS | AKT2, PIK3CA, AKT3 | AKT1 4/4885RPS6KB1 41/4885PRKCB 176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.